Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00215566
Status:
COMPLETED
Last Update Posted:
2007-05-28
First Post:
2005-09-19
Brief Title:
A Study to Evaluate the Safety Tolerability and Pharmacodynamics of DDP733 for IBS-c
Sponsor:
Dynogen Pharmaceuticals
Organization:
Dynogen Pharmaceuticals
Study Overview
Official Title:
A Phase 2a Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety Tolerability and Pharmacodynamics of Multiple Doses and Dose Levels of DDP733 in Patients With Irritable Bowel Syndrome With Constipation
Status:
COMPLETED
Status Verified Date:
2006-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety tolerability and pharmacodynamics of the investigational drug DDP733 in treating subjects with IBS-c A placebo control will be utilized
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None